We Wouldn't Be Too Quick To Buy Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369) Before It Goes Ex-Dividend
We Wouldn't Be Too Quick To Buy Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369) Before It Goes Ex-Dividend
Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369) stock is about to trade ex-dividend in 3 days. The ex-dividend date occurs one day before the record date which is the day on which shareholders need to be on the company's books in order to receive a dividend. The ex-dividend date is important as the process of settlement involves two full business days. So if you miss that date, you would not show up on the company's books on the record date. Therefore, if you purchase Zhejiang Gongdong Medical Technology's shares on or after the 9th of July, you won't be eligible to receive the dividend, when it is paid on the 9th of July.
拱東醫療股票將於3天后的除息日開始交易。除淨日是股東需要出現在公司名冊上以領取股息的前一天。除息日非常重要,因爲結算過程涉及兩個完整的工作日。所以,如果你錯過了這個日期,你將不會在記錄日期出現在公司名冊上。因此,如果你在7月9日或之後購買拱東醫療的股票,當股息在7月9日支付時,你將無法獲得補償。
The company's next dividend payment will be CN¥0.30 per share, and in the last 12 months, the company paid a total of CN¥0.80 per share. Looking at the last 12 months of distributions, Zhejiang Gongdong Medical Technology has a trailing yield of approximately 2.0% on its current stock price of CN¥39.60. Dividends are a major contributor to investment returns for long term holders, but only if the dividend continues to be paid. So we need to check whether the dividend payments are covered, and if earnings are growing.
該公司的下一個股息支付爲人民幣0.30元每股,在過去的12個月中,該公司每股支付了人民幣0.80元。從過去的12個月的分配來看,拱東醫療的股票當前的收益率大約爲2.0%。股息是長揸者投資回報的主要貢獻者,但前提是股息繼續支付。所以我們需要檢查股息支付是否得到覆蓋,並且盈利是否增長。
If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Zhejiang Gongdong Medical Technology is paying out an acceptable 72% of its profit, a common payout level among most companies. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. It paid out 102% of its free cash flow in the form of dividends last year, which is outside the comfort zone for most businesses. Companies usually need cash more than they need earnings - expenses don't pay themselves - so it's not great to see it paying out so much of its cash flow.
如果公司支付的股息超過了其收益,那麼股息可能會變得不可持續 - 這絕非理想的情況。拱東醫療的股息支付了可接受的72%的利潤,這是大多數公司普遍支付的比率。然而,與利潤相比,現金流甚至更重要,用於評估分紅。因此我們需要看看公司是否有足夠的現金來支付其分配。拱東醫療去年以自由現金流的形式支付了其102%的股息分配,這超出了大多數企業的舒適區。公司通常需要現金而不是利潤--支出不能自行支付--所以看到公司支付了太多的現金流出並不好。
Zhejiang Gongdong Medical Technology does have a large net cash position on the balance sheet, which could fund large dividends for a time, if the company so chose. Still, smart investors know that it is better to assess dividends relative to the cash and profit generated by the business. Paying dividends out of cash on the balance sheet is not long-term sustainable.
拱東醫療在資產負債表上有大量的淨現金頭寸,如果公司選擇,可以爲時長時間支付大量的股息。但是,明智的投資者知道根據業務所產生的現金和利潤來評估股息更好。從資產負債表上的現金支付股息是不可持續的。
Zhejiang Gongdong Medical Technology paid out less in dividends than it reported in profits, but unfortunately it didn't generate enough cash to cover the dividend. Were this to happen repeatedly, this would be a risk to Zhejiang Gongdong Medical Technology's ability to maintain its dividend.
拱東醫療支付的股息比其報告的利潤少,但不幸的是,它沒有產生足夠的現金來支付股息。如果這種情況反覆發生,這將是拱東醫療維持其股息能力的一種風險。
Click here to see the company's payout ratio, plus analyst estimates of its future dividends.
點擊此處查看公司的支付比率以及未來分紅的分析師預期。
Have Earnings And Dividends Been Growing?
收益和股息一直在增長嗎?
Companies that aren't growing their earnings can still be valuable, but it is even more important to assess the sustainability of the dividend if it looks like the company will struggle to grow. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. That explains why we're not overly excited about Zhejiang Gongdong Medical Technology's flat earnings over the past five years. Better than seeing them fall off a cliff, for sure, but the best dividend stocks grow their earnings meaningfully over the long run. Earnings have been growing somewhat, but we're concerned dividend payments consumed most of the company's cash flow over the past year.
即使公司沒有增長其收益,它仍然可能具有價值,但是如果看起來公司將難以增長,那麼評估分紅的可持續性就更加重要了。投資者喜歡股息,因此如果收益下降並且股息減少,就預計股票將同時大量拋售。這就解釋了爲什麼我們對拱東醫療在過去五年中的平坦收益並不是太興奮。肯定比看到它們暴跌要好,但是最好的股息股票在長期內有意義地增長其收益。儘管盈利有所增長,但我們擔心股息支付在過去一年中消耗了公司大部分現金流。
Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Zhejiang Gongdong Medical Technology's dividend payments per share have declined at 15% per year on average over the past three years, which is uninspiring.
衡量公司股息前景的另一個關鍵方式是通過衡量其歷史股息增長率。拱東醫療過去三年平均每股股息支付下降了15%,令人失望。
Final Takeaway
最後的結論
From a dividend perspective, should investors buy or avoid Zhejiang Gongdong Medical Technology? Zhejiang Gongdong Medical Technology is paying out a reasonable percentage of its income yet an uncomfortably high 102% of its cash flow as dividends. What's more, earnings have barely grown. It's not that we think Zhejiang Gongdong Medical Technology is a bad company, but these characteristics don't generally lead to outstanding dividend performance.
從股息的角度來看,投資者該買還是避免拱東醫療?拱東醫療支付了合理比例的收入,但不舒適地支付了102%的現金流作爲股息。更重要的是,盈利幾乎沒有增長。我們並不認爲拱東醫療是一個壞公司,但這些特徵通常不會帶來卓越的分紅業績。
Having said that, if you're looking at this stock without much concern for the dividend, you should still be familiar of the risks involved with Zhejiang Gongdong Medical Technology. For example, we've found 2 warning signs for Zhejiang Gongdong Medical Technology that we recommend you consider before investing in the business.
儘管如此,如果您沒有過多關注股息而觀察此股票,您仍應熟悉拱東醫療公司的風險。例如,我們已發現2個有關拱東醫療的警示信號,我們建議您在投資該公司之前考慮它們。
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
一般來說,我們不建議僅僅購買第一個股息股票。下面是一個經過策劃的有趣的、股息表現良好的股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com